This site is intended for healthcare professionals

Alnylam reports positive topline results from ILLUMINATE-B phase III study of lumasiran for the treatment of primary hyperoxaluria type 1 in children under the age of six.

Read time: 1 mins
Last updated:16th Mar 2021
Published:1st Oct 2020
Condition: Hyperoxaluria
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest